Warren Buffett and Greg Abel Keep Overlooking This Stock -- but It's One of the Most Berkshire-Ready Picks on the Market
Yahoo Finance ·
Berkshire Hathaway 's ( BRKA -1.08% ) ( BRKB -1.15% ) second-quarter 13F is now officially filed, disclosing all the stock trades it made during the quarter, and ultimately offering a snapshot of the conglomerate's current stock portfolio. No real surprises either. Although Berkshire was a net buyer for the first time in a long time, the additions were expansions of existing positions, or new purchases that make enough sense. There's one name arguably worth Warren Buffett 's and Greg Abel's consideration, however, that still isn't a Berkshire Hathaway holding. That's drugmaker Pfizer ( PFE +0.30% ) . Here's why Berkshire should buy it, and why you might want to even if Abel or Buffett don't end up adding it to Berkshire Hathaway's portfolio anytime soon. If you know anything at all about Pfizer, then you might disagree with the call. This pharmaceutical stock has underperformed since peeling back from its COVID-prompted peak in late 2021. In fact, it's gone nowhere since early 2024, unable to offset the massive revenue decline resulting from the wind-down of the coronavirus pandemic. The company wasn't able to do a great deal of developmental work during that period; shareholders have paid the price in the meantime.
AI 시장 분석
Following the filing of Berkshire Hathaway's Q2 13F, Pfizer (PFE) is gaining attention as an undervalued stock that Warren Buffett and Greg Abel have yet to purchase. Despite experiencing sharp revenue declines and sluggish stock performance following the end of the COVID-19 vaccine boom, Pfizer possesses potential that aligns with Berkshire's investment philosophy. Regardless of whether Buffett adds it to his portfolio, investors need to reassess the valuation appeal of the pharmaceutical sector.
상승 영향
- Biotechnology — The undervaluation appeal of major pharmaceutical companies like Pfizer is coming to light, and depending on future drug pipeline performance, overall sector sentiment could improve.
하락 영향
- Biotechnology — Ongoing sharp revenue declines following the end of the COVID-19 boom and the risk of delayed new drug development are acting as factors pressing down on earnings.
DYAX 전담 분석
Although Berkshire Hathaway maintained a net buying stance during the second quarter, pharmaceutical stock Pfizer, which has struggled to recover since the peak of the COVID-19 pandemic, remains excluded from the portfolio. This is primarily due to declining post-pandemic sales and a drop in stock prices driven by stagnation in new drug development.
Future stock price trends will be determined by whether Pfizer successfully launches new blockbuster drugs to fill the revenue gap left by COVID-related products. Key indicators to watch include quarterly R&D investment efficiency and the commercialization speed of its drug pipeline, with the risk of further stock declines if it fails.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 48% · Bearish (Short) 52%
553 participants
Related News
- Trident Digital Tech Holdings (Nasdaq: TDTH) Executes Joint Venture to Deploy the IRMA AI Engine to Three Continents and Markets Representing Approximately 9.4 Million Businesses With Digital Innovations Group
- BIM Birlesik Magazalar 주식, 오늘 왜 급등했나?
- Google Buys a Dead Airline's Internal Emails to Train AI
- Netwrix Extends Identity Security to AI Agents in Microsoft Entra ID
- NVIDIA’s $500 Billion AI Bet Is ‘Almost Like a Digital Infrastructure Bill’
- Tesla Tests Cybercab on Employees First in Austin Rollout
